Balanced news tone
News Sentiment
VIR sentiment intelligence
Vir Biotechnology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-0.8% over one week, +15.7% over four weeks, trend active, and near fair-value range.
Hillsdale Investment Management Inc. Invests $1.44 Million in Vir Biotechnology, Inc. $VIR
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Hillsdale Investment Management Inc. Invests $1.44 Million in Vir Biotechnology, Inc. $VIR
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 09:15
- Source
- MarketBeat
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Vir Biotechnology, Inc. $VIR Shares Bought by Candriam S.C.A.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 08:26
- Source
- MarketBeat
Y Intercept Hong Kong Ltd Takes Position in Vir Biotechnology, Inc. $VIR
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 18:17
- Source
- MarketBeat
Vir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 07:00
- Source
- MarketBeat
[144] Vir Biotechnology, Inc. SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 07:00
- Source
- Stock Titan
Vir Biotechnology (VIR) Stock Could Be 56% Undervalued After New PSMA Data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jun 2026 07:00
- Source
- simplywall.st
Is Vir Biotechnology (VIR) Quietly Recasting Its Governance Strength With a New Audit Committee Chair?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- simplywall.st
Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 18 Jun 2026 05:53
- Source
- TradingKey
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- TradingView
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Stock Titan
Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Stock Titan
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 07 Jun 2026 07:00
- Source
- Market source
How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 May 2026 14:13
- Source
- Simply Wall St.
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 May 2026 15:19
- Source
- Motley Fool
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 May 2026 07:00
- Source
- The Motley Fool
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Investing.com
PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Quiver Quantitative
PDS Biotechnology Q1 Earnings Call Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- TradingView
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 29 Apr 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Apr 2026 07:00
- Source
- Market source
Vir Biotechnology closes $240M Astellas deal for cancer drug
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 16 Apr 2026 07:00
- Source
- Investing.com